



WORLD CONGRESS USA

10-11 OCTOBER 2018 | CONVENE ONE BOSTON PLACE | BOSTON | MA



STRATEGY, INVESTMENT AND PARTNERING FOR LIFE SCIENCE EXECUTIVES

ORGANISED BY:



The network for life science executive leaders

FORMERLY KNOWN AS **biotechandmoney**
bringing deals to life

PLATINUM SPONSORS



GOLD SPONSORS

COVINGTON



SILVER SPONSORS



WILMER CUTLER PICKERING HALE AND DORR LLP

CORPORATES, INVESTORS, KOLS AND PHARMA... THE LSX WORLD CONGRESS USA IN 2018!

The LSX World Congress USA is a high-calibre, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science companies need to enable more effective investment, planning and strategic growth within their businesses. The US edition of the World Congress follows on from five previous highly successful congresses following the unique style and format of LSX, formerly Biotech and Money.

With our relentless focus on quality peer-to-peer discussion, high-level networking and partnering, unique formats and a vetted, high-calibre audience, we bring together the people that matter to the future of healthcare.

7 REASONS TO ATTEND...

- UNDERSTAND...** the latest trends, forecasts and insights from leading investment funds, life science company executives, pharma BD&L heads and industry KOLs
- NETWORK...** with 300+ life science CxOs, investors and pharma convening to address key executive issues facing their businesses and the wider healthcare sector
- LISTEN TO...** war stories, advice and key success factors from CEOs who have gone public, secured big licensing deals or raised significant fund privately in our fireside chats
- PRESENT...** your company to an audience of qualified investors and pharma BD&L in the Inv€\$table showcase sessions
- MEET AND PARTNER...** through the exclusive LSX 1-2-1 partnering system to find investors, scout investment opportunities and connect with potential partners
- JOIN...** intimate workshops run by the industry's foremost experts to help prepare your company for key milestones and explore innovative models for company growth
- CONNECT WITH PURPOSE...** to our community - the life science executives of LSX.

Pre-Day - IPO BOOTCAMP

9.00

The US IPO Bootcamp is a full-day forum in which a team of some of the world's foremost experts, advisers, bankers and consultants help 8 CEOs and CFOs navigate the how, what, where and when of a successful US IPO. The key USPs are a very high level and calibre of attendee and program, exclusivity, and a personalised approach.

In addition to 'no holds barred' discussions, it features tailored sessions, where each registering executive and company receive individual attention from the experts to talk through strategy, tactics, mechanics and ideas unique to them.

Discussions include, but are not limited to:

- Keynote address: the current state of capital markets
- Anatomy of an IPO: Back to back case study discussions of recent IPOs.
One will feature a recent success story and one where the outcome was below expectation
- Determining and defining your IPO strategy
- Legal preparations
- Financial PR and communications
- Regulatory requirements and IPO checklists

Co-Hosts:

 COVINGTON

 Nasdaq

 OPPENHEIMER

 LaVoie Health Science
Strategic Communications

 pwc

17.00

CLOSE OF BOOTCAMP

Day 1 - Plenary Track

9.00

KEYNOTE ADDRESS: CAPITAL MARKETS OUTLOOK

Marshall Smith, Head of Global Healthcare, Goldman Sachs

9.20

KEYNOTE FIRESIDE CHAT: A NEW MODEL FOR DISRUPTIVE VALUE CREATION: INSTITUTIONAL ENTREPRENEURIAL INNOVATION

Noubar Afeyan, Founder and CEO, Flagship Pioneering
Surani Fernando, Editor, North America at GlobalData Healthcare (moderator)

9.40

KEYNOTE PANEL: EARLIER DEALS, LARGER ROUNDS AND NEW CAPITAL: MACRO VENTURE TRENDS

Industry leading investors discuss how the venture capital industry is evolving, the macro-trends driving the rise of the mega-round and earlier investments, and the new capital sources helping fund the next wave of innovation.

- What strategies are industry-leading investors taking to drive the sector forward?
- With capital flowing in to companies from VC, CVC, crossover investors and emerging markets funds, what could the investment landscape look like in 5 years
- How are US investment leaders bridging the gap to ensure EU companies gain access to US capital markets, and North American companies access to partnership, development and innovation opportunities

Lewis Geffen, Co-Chair, Life Sciences and VC & Emerging Companies Practice, Mintz Levin (moderator)
Dylan Morris, Partner, CRV
Paulina Hill, Principal, Polaris Partners
Christopher de Souza, Director, Broadview Ventures

10.20

KEYNOTE PANEL: CHALLENGES AND OPPORTUNITIES FOR PHARMA BD IN 2019

Global heads from big pharma and big biotech discuss the drivers behind the most active period of M&A in a decade, and the impacts of political reforms in the healthcare sector.

- What are the drivers of increased M&A activity? Will the trend continue?
- Where are the hot areas for growth and exciting areas of development?
- How can companies best position themselves and create optimal opportunities in the eyes of pharma?
- What impact are US tax reforms having on pharma and what are the perspectives on the impact of the US drug pricing debate?

Jerry Lee, Managing Director, Goldman Sachs (moderator)
Nigel Sheail, Global Head of M&A and BD&L, Novartis
Doug Giordano, SVP Worldwide BD, Pfizer
Boris Zaitra, Global Head of M&A, Roche
Aradhana Sarin, SVP, Head of BD & Strategy, Alexion Pharmaceuticals
Paul Biondi, SVP, Strategy and Business Development, Bristol Myers Squibb

11.00

NETWORKING BREAK

11.30

PANEL: REDEFINING EARLY SCIENCE: INVESTING EARLY AND INVESTING LONGER

VCs going long with their life science investments discuss and share their views on the success of the patient capital model, and look to the future of investment strategy and backing new technologies.

- With the healthy IPO market delivering returns for VCs, what is now the strategy for continued patient capital support for the next wave of companies?
- How else are investors supporting their portfolio companies, beyond the full-service investment view and backing through multiple rounds?
- What next; where are the most exciting areas of innovation for investors with a longer-term perspective?

Lewis Geffen, Co-Chair, Life Sciences and VC & Emerging Companies Practice, Mintz Levin (moderator)
Arjun Goyal, Co-Founder, Vida Ventures
Andrew Elbardissi, Principal, Deerfield
Aaron Kantoff, Principal, Apple Tree Partners
Brett Zbar, Managing Director, Foresite Capital Management
Mark Chin, Investment Director, Aris Bioscience

12.10

FIRESIDE CHAT: CONNECTING WITH CREATIVITY

Ivana Magovčević-Liebisch, EVP & Chief Business Officer, Ipsen
Surani Fernando, Editor, North America at GlobalData Healthcare (moderator)

12.30

PANEL: CVCs AUGMENTATION OF EARLY STAGE INNOVATION

The most active corporate venture arms of big pharma debate how their role in funding innovation and supporting early and growth stage companies is changing.

- How do CVC's fit in the evolving venture funding landscape?
- In what ways are CVCs now syndicating with VCs earlier?
- What is the impact of these agreements on corporates and the wider investment sector?

Asher Rubin, Global Head, Life Sciences Industry Group, Hogan Lovells (moderator)
Jason Hafler, Senior Director of Investments, Sanofi Ventures
Alicia Irurzun-Lafitte, Principal, M Ventures
Jamie Kasuboski, Director, Boehringer Ingelheim Venture Fund USA
Michal Silverberg, Managing Director, Novartis Venture Fund

13.10

NETWORKING LUNCH

14.10

PANEL: CULTIVATING THE FAST GROWERS CLUB; FROM LAUNCH TO MASSIVE FUNDRAISE

Investors creating and backing exciting start-ups with mega rounds, and the executives leading them, share their views on building a new wave of early and well-funded corporates.

- Will the boom in early and larger rounds to catapult innovation to the clinic continue? How long can it last?
- How are risks being mitigated on such big early investments?
- How are executives of mega-backed companies planning to expedite growth and deliver returns?

Rosemary Reilly, Partner, WilmerHale (moderator)

Todd Foley, Managing Director, MPM Capital

Neil Exter, Partner, Third Rock Ventures

Alexandra Glucksmann, CEO, Cedilla Therapeutics

Jim Broderick, CEO, Palleon Pharmaceuticals

Philip Lee, COO and Co-Founder, Senti Biosciences

14.50

FIRESIDE CHAT: FOSTERING INNOVATION TO ACCELERATE COMPANY GROWTH

Chandra Ramanathan, Vice President & Head, East Coast Innovation Centre, Bayer

Surani Fernando, Editor, North America at GlobalData Healthcare (moderator)

15.10

PANEL: NOUGHTS AND CROSSOVERS; VALUATIONS, ROUND SIZES AND UNCONVENTIONAL CAPITAL SOURCES

Crossover investors, and the executives who have been backed by them, discuss successfully fuelling the buoyant healthcare IPO market and the strategy pre and post-listing.

- Taking a longer-term view of patient capital and even permanent capital in healthcare investment
- With such big VC rounds, how big is the risk of future down rounds and valuation compression for companies and crossover investors? How can these risks be mitigated?
- What role are emerging markets funds and new sources of capital playing in late stage financing?
- CEOs' perspectives on the importance and value of crossover financiers

Giovanni Mariggi, Partner, Medicxi

Philip Astley-Sparke, Venture Partner, Forbion Capital Partners

15.50

NETWORKING BREAK

16.20

ADDRESSING KEY CHALLENGES IN IMMUNO-ONCOLOGY COMBINATION TRIALS

Jai Balkissoon, VP, Immuno-Oncology Global Product Development, PPD Biotech

KEYNOTE FIRESIDE CHATS: 'ANATOMY OF...'

16.40

AN UPSIZED IPO

Geoff Mackay, CEO, AvroBio

Michael Fitzgerald, Managing Director, Nasdaq (moderator)

17.00

BUILDING A GENE THERAPY PORTFOLIO FOR SUCCESS

Pavan Cheruvu, CEO, Axovant

Donna LaVoie, President and CEO, LaVoieHealthScience (moderator)

17.20

A CLINICAL-STAGE ACQUISITION

Brian Pereira, CEO, Visterra

Paul Sagan, AVP, Investor Relations and Corporate Communications, LaVoieHealthScience (moderator)

17.40

EXECUTIVE NETWORKING RECEPTION

Day 1 - Showcases



The Inv€\$table tracks will feature 15 and 10 minute presentations from a selection of exciting and innovative life sciences companies from the US and Europe who are looking to connect with capital and partners.

Featuring sections for growing US and EU companies, as well as a section for an early-stage innovation track for the next wave of US life science innovation!

11.30

11.30 Alexandra Glucksmann, CEO
Cedilla Therapeutics



Thomas Forest-Farb, CEO
Thrive Bioscience



11.45 David Benschhof Klein, CEO
Click Therapeutics



Patrick Lu, CEO
Sirnaomics



12.00 Greg Gorgas, CEO
Artelo Biosciences



Josep Bassaganya-Riera, CEO
Landos Biopharma



12.15 Shelley Margetson, CEO
Gadeta



David DeWahl, CEO
Ischemix



12.30 Igor Sherman CEO
Alpha Cancer Technologies



Michael Schrader, CEO
Vaxess Technologies



12.45 Bradley Messmer, CEO
Abreos Biosciences



NETWORKING LUNCH

13.10

14.10

14.10 Cliff Holloway, CEO
Scancell



14.25 Catherine Pickering, CEO
iOnctura



14.40 Julian Howell, Co-Founder & MD
PharmaKrysto



14.55 Gerben Moolhuizen, CEO
ISA Pharmaceuticals



15.10 David Harper, CEO
Evolution Biotechnologies



15.25 Clive Morris, CEO
Inivata



NETWORKING BREAK

15.50

16.20

16.20 Thomas Ryan, CEO
Theromics



16.28 R Dana Ono, CEO
NanoDe Therapeutics

16.36 Sarah Kalil, CEO
CoreMap



16.44 John Deacon, Founder, President
Cytosolix



16.52 Nicole Wagner, CEO
LambdaVision



17.00 Lee Wright, VP of Research
Quercus Molecular Design



17.08 Caroline Rufo, Blavatnik Fellow
Pattern Therapeutics



17.16 Jonathan Fenstad, Founder, CEO
NeuroCyte Therapeutics



17.30

NETWORKING DRINKS

Day 1 - Satellite Forum

11.00

NETWORKING BREAK

11.30



PHARMA BD LEADERS FORUM

Invite only forum designed for global and regional BD heads from Pharma and large-cap Biotech companies. A Chatham House Rule forum in which industry leaders discuss and shape the future of their sector with peers.

Pfizer, Novartis, Roche, AstraZeneca, Boehringer Ingelheim, BMS, Alexion, Abbvie, Bayer, EMD Serono, Eli Lilly, Ipsen (CONFIRMED)

Co-Hosts:



13.10

NETWORKING LUNCH

14.10



PHARMA BD LEADERS FORUM

Invite only forum designed for global and regional BD heads from Pharma and large-cap Biotech companies. A Chatham House Rule forum in which industry leaders discuss and shape the future of their sector with peers.

Pfizer, Novartis, Roche, AstraZeneca, Boehringer Ingelheim, BMS, Alexion, Abbvie, Bayer, EMD Serono, Eli Lilly, Ipsen (CONFIRMED)

Co-Hosts:



15.50

NETWORKING BREAK

1-2-1 PARTNERING



The Congress provides dedicated out of session networking time to hold those all important face-to-face meetings. To ensure you maximise this time, we will provide attendees access to Meeting Mojo, the Congress' 1-2-1 partnering app, to create an online profile, search for potential partners and book meetings.

The partnering system will go live around 3 weeks prior to the event. Meetings arranged through Meeting Mojo will be allocated a table in the partnering area at the Congress.

For more information please contact Emily Vipond, Head of Investor Relations on emily@biotechandmoney.com

Day 2 - Plenary Track

9.00

KEYNOTE PANEL: PRICING, PATIENTS AND PAYMENTS; A VALUE-BASED APPROACH

Executives, regulators, payers and experts discuss and debate the outcomes-driven, patient-centric approach and how this can be actioned, monitored and rewarded.

- How can the industry as a whole manage the cultural shift towards a patient-centric culture and recognise, reward, and repeat behaviours to ensure it is sustained
- What are appropriate and measurable strategies to ensure alignment in patient value and shareholder value? What are the major risks?
- How can patients be enabled and empowered to have their voices heard?
- What roles do biotech, pharma, payers, providers and regulators have to play in this shift?

Brian Rye, Sr. Health-Care Policy Analyst, Government Team, Bloomberg Intelligence (moderator)

Michael Sherman, SVP and Chief Medical Officer, Harvard Pilgrim Health Care

Bruce Leicher, SVP and General Council, Momenta Pharma

Bob Ward, Chairman and CEO, Eloxx Pharmaceuticals

Marianne Hamilton Lopez, Research Director of Value-Based Payment Reform, Duke-Margolis

9.40

FIRESIDE CHAT: FROM A POSITION OF GLOBAL LEADERSHIP IN GENOMICS: WHAT'S NEXT(CODE)?

Rob Brainin, CEO, WuXI NextCODE

Steve Abrams, Partner, Global Life Sciences Leadership Team, Hogan Lovells (moderator)

10.00

KEYNOTE PANEL: DIGITAL THERAPEUTICS; REBOOTING THE TRADITIONAL PHARMA MODEL?

Digital health leaders, all with their own technologies and approaches to disrupting the traditional healthcare model, explain how they have grown and developed their businesses and what lies ahead.

- What was the process and key success factors behind landmark regulatory approvals of digital health products?
- What are the next steps and strategies for commercialisation of these innovative and approved treatments and solutions?
- Which key partnerships and business models are vital for helping digital health come of age and reach the mainstream of patient care?

Kimberly Ha, Founder and CEO, KKH Advisors (moderator)

Russ Johannesson, CEO, Glooko

Adam Kaufman, CEO, Canary Health

Joris Van Dam, Head Digital Therapeutics, Novartis

Eddie Martucci, CEO, Akili Interactive

David Benshoof Klein, CEO, Click Therapeutics

10.40

NETWORKING BREAK

11.10

PANEL: I, BIOTECH; AI IN HEALTHCARE

Executives and investors discuss the various exciting applications of AI, the progress made so far using AI in drug discovery and healthcare, as well as looking to the future of the technology's application.

- How analysing massive data sets with AI is revolutionising the way companies can generate novel drug candidates
- What should investors be looking for when considering AI investments?
- Which doors can advancing AI technology open for healthcare over the next 10 years?

Kimberly Ha, Founder and CEO, KKH Advisors (moderator)

Dennis Grishin, Co-Founder, Nebula Genomics

Niven Narain, CEO, BERG Health

Ed Addison, CEO, Cloud Pharmaceuticals

Sandy Li, Vice President, Baidu Ventures USA

11.50

PANEL: ANALYZE THIS...BIG DATA DRIVEN INNOVATION

Executives of life science companies, and pharma harnessing the power of big data explain the huge opportunities it can offer now, and in the future, in drug discovery and development.

- What opportunities does big data analysis and evolution present to life sciences and healthcare?
- In what ways are biotech, pharma and tech companies disrupting traditional models with data analytics?
- With the rise in smart devices, wearables and sensors, how big is the potential for big data tech to analyse and provide outcomes from previously untapped data?

Doug Russell, SVP & General Manager, LaVoieHealthScience (moderator)

Leila Pirhaji, Founder and CEO, ReviveMed

Josh Mandel-Brehm, CEO, CAMP4 Therapeutics

Gini Desphande, Founder and CEO, NuMedii

Alex de Winter, Managing Director, GE Ventures

Janna Hutz, Senior Director, Head of Human Biology & Data Science, Eisai

12.30

PANEL: THE DIGITAL VALUE OF BLOCKCHAIN

Executives from companies at the forefront of the industry explain how and why the life sciences and healthcare sector can benefit in multiple ways from blockchain technology.

- Monitoring and recording of multiple service provider activities involved in product development and smart contracts for seamless contract fulfilment
- Enabling streamlined and immutable global clinical trial management
- Empowering patients with a full picture of their medical records and data

Jay Goth, Managing Partner, Forentis Fund (moderator)

Chrissa McFarlane, CEO, Patientory

David Koepsell, CEO, EncrypGen

Drew Volpe, Founding Partner, First Star Ventures

13.10

NETWORKING LUNCH

14.10

PANEL: SEEKING HIGH RETURNS WITH CANNABINOIDS

Executives and investors who are investing in the area, debate the exciting possibilities of cannabinoid therapeutics to treat a range of diseases.

Terry O'Dwyer, Co-CEO, LSX (moderator)

Dean Petkanas, CEO, Kannalife Sciences

Karan Wadhwa, Managing Partner, Casa Verde Capital

Neil Mahapatra, Chairman, Oxford Cannabinoid Technologies

Greg Gorgas, CEO, Artelo Biosciences

14.50

PANEL: THE AGE OF LONGEVITY: GO LONG!

Executives and investors have an interactive discussion and debate on the potential and obstacles in the longevity industry, and the scientific and medical innovations that could further extend human life.

- The dawn of the Longevity Industry; how life science companies are translating biological research to real-world products that extend healthy lifespan
- What are the most exciting advances and new technologies in the science of healthy ageing?
- Which financial structures and investment strategies are needed to support the growing longevity industry?

Terry O'Dwyer, Co-CEO, LSX/Longevity Leaders (moderator)

Scott Shandler, CEO, Longevity Biotech

George Church, Professor of Genetics, Harvard Medical School

Thomas Hughes, CEO, Navitor Pharmaceuticals

15.30

PANEL: GOING WITH YOUR GUT: COMMERCIALIZING THE MICROBIOME

Executives driving forward one of the fastest growing areas of precision medicine discuss what is needed to translate increased understanding of the microbiome into innovative diagnostics and therapeutics.

- Unlocking the potential of the microbiome; how close are we and what is needed to realise this potential?
- Which areas of research are showing the most progress?
- What are the biggest hurdles to microbiome commercialisation?
- Demonstrating value to investors and pharma

Terry O'Dwyer, Co-CEO, LSX (moderator)

Mark Smith, CEO, Finch Therapeutics

David Donabedian, CEO, AXIAL Biotherapeutics

Philip Strandwitz, CEO, HoloBiome

Todd Krueger, CEO, AOBiome

Sohang Chatterjee, CEO, EnBiome Therapeutics

16.10

NETWORKING BREAK AND 1-2-1 PARTNERING

16.30

CLOSE OF CONGRESS

REGISTERED INVESTORS INCLUDE...



KEY FEATURES OF THE CONGRESS



WORLD CONGRESS USA

KEYNOTE SESSIONS WITH LEADING LIFE SCIENCE EXECUTIVES AND INVESTMENT FUNDS

EXPERT PRESENTATIONS AND PANEL DISCUSSIONS TACKLING KEY ISSUES FOR LIFE SCIENCE CxOs

PRE-EVENT 1-2-1 PARTNERING SYSTEM TO SEARCH, QUALIFY AND ARRANGE ON-SITE MEETINGS

GLOBAL CONFERENCE LEVERAGING LSX'S POSITION AS A LEADING LIFE SCIENCE EXECUTIVE COMMUNITY



INVESTABLE

CEOs from the most progressive drug discovery, research and development companies present their company to qualified investors and pharma BD&L heads.

Across two tracks of showcases and in three 1.5 hour sections, six companies present for 15 minutes including a Q&A.



PHARMA BD LEADERS FORUM

A high profile and invitation-only forum for heads of global BD&L at the world's largest pharma companies.

Held under Chatham House Rule, the Pharma BD Forum is only for leading pharma executives and their key influential partners.

VENUE - CONVENE, ONE BOSTON PLACE



Convene at One Boston Place is a state-of-the-art meeting, event, and conference space in the heart of Boston's Financial District.

Convene is the perfect place to bring together life science leaders, innovators and investors together for the LSX World Congress USA.

We look forward to hosting you!

201 Washington Street, 2nd Floor, Boston, MA 02108

SPONSORSHIP AND PARTNERSHIP OPPORTUNITIES

LSX World Congress USA offers a unique opportunity to position yourself as an expert partner of choice in front of a C-level life science audience.

The two-day forum combines big picture keynote presentations, interactive and engaging panel discussions and debates, alongside focussed workshops and invite-only CEO roundtables.

Our attendee list is curated to ensure delegates represent genuine industry leaders from life science corporates, investors and pharma.

A sponsorship role at the event will offer the following benefits:



Get face-to-face time with well matched, fully profiled target clients from the LSX executive community.



Demonstrate your thought leadership in front of a senior audience of life science professionals.



Lock out your competitors by taking an exclusive co-host role in one of our workshops or therapeutics forums.



Secure a seat at the table as some of the world's foremost life science leaders discuss their biggest opportunities and challenges.



Align your company brand with an initiative that's striving to find genuine solutions for the life science CxO community.

SPONSORSHIP AND PARTNERSHIP ENQUIRIES

Matt Pullan, SVP

matt@lsxleaders.com +44 (0) 203 637 5908



WORLD
CONGRESS
USA



LSX | CONNECT WITH PURPOSE

PARTNERSHIP ENQUIRIES

Matt Pullan, SVP
matt@lsxleaders.com
+44 (0) 203 637 5908

SPEAKER AND AGENDA ENQUIRIES

Neil Darkes, Co-CEO
neil@lsxleaders.com
+44 (0) 203 637 5908

Josh Dance, SVP
josh@lsxleaders.com
+44 (0) 203 637 5908



The network
for life science
executive leaders

LSX Ltd. | Suite 132 | Business Design Centre | 52 Upper St. | London | N1 0QH